{
  "id": 267710,
  "title": "STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more",
  "url": "https://urgent.news/2026/08/07/stat-pharmalittle-were-reading-about-replimunes-melanoma-drug-a",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-07T13:18:05.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/08/07/replimune-melanoma-drug-medicare-policy-change/"
  },
  "original_language": "en",
  "account": "The U.S. Food and Drug Administration recently approved the treatment for advanced melanoma, a significant victory for the biotech company Replimune following a difficult approval process. This approval came after FDA advisers voted in favor of the treatment, Tudriqev, despite concerns over the trial design and conduct. The majority felt there was sufficient evidence of efficacy and that patients urgently needed new treatments. However, a little-known policy change by Medicare inadvertently caused a seven-year delay in negotiating a price for a costly AbbVie medicine. This decision, made by the Centers for Medicare and Medicaid Services (CMS) before they entered price negotiations, ultimately benefited AbbVie and potentially other drugmakers.",
  "summary": "Eli Lilly and Novo Nordisk convinced a federal judge to toss an antitrust lawsuit by a compound pharmacy",
  "key_points": [
    "FDA approves Replimune's Tudriqev for advanced melanoma",
    "Medicare policy change delayed price negotiation by 7 years",
    "AbbVie benefited from CMS's decision before price talks"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}